Medicinal Products Prices

Dáil Éireann Debate, Tuesday - 6 December 2016

• Debates
• Find a debate
  • Dáil debates
  • Seanad debates
  • Committee debates
• Find a vote
  • Dáil votes
  • Seanad votes
  • Committee votes
• Parliamentary questions
  • Written questions
  • Oral questions
• Search tips
• Utterances having an adverse effect

Tuesday, 6 December 2016

Questions (347)

Louise O'Reilly

Question:

347. Deputy Louise O'Reilly asked the Minister for Health the number of drugs where, following the NCPE, National Centre for Pharmacoeconomics, assessment of the manufacturer's economic dossier on the cost effectiveness of a drug (details supplied), the NCPE found a drug not to be cost effective; if this information will be provided for each of the past five years with a breakdown of whether additional price reductions were successfully negotiated and agreed upon; and if he will make a statement on the matter. [38604/16]

Written answers

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply.

Question No. 348 answered with Question No. 345.

• Previous Answer
• Next Answer